News
Novo Nordisk, GoodRx and Wegovy
Digest more
Health Hims & Hers Will Sell Wegovy-Like Weight Loss Drugs for $199 The telehealth company's stock surged after the announcement Bruce Gil, Quartz Published May 20, 2024 | Comments (13) 𝕏 ...
What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.
Novo Nordisk cut ties with Hims & Hers over semaglutide concerns Company alleges illegal sales of unapproved Wegovy alternatives FDA limits compounding of GLP-1 drugs to patient-specific cases ...
On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on ...
Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...
Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a new, affordable price. The company, via this offer, aims to make proven ...
On Tuesday, Hims & Hers announced a long-term collaboration with Denmark-based Novo Nordisk A/S (NVO), which makes Wegovy and diabetes-treatment Ozempic, which are both approved by the FDA.
SAN FRANCISCO, May 22, 2025--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback